First-In-Human Phase I Study Of Arv-110, An Androgen Receptor (Ar) Protac Degrader In Patients (Pts) With Metastatic Castrate-Resistant Prostate Cancer (Mcrpc) Following Enzalutamide (Enz) And/Or Abiraterone (Abi).
JOURNAL OF CLINICAL ONCOLOGY（2020）
摘要
3500Background: Proteolysis Targeting Chimera (PROTAC) protein degraders induce selective degradation of targeted proteins by engaging the ubiquitin proteasome system. ARV-110 is an orally bioavail...
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要